Use of Apheretic Technologies in Cardiovascular Disease

University of Pavia

Overview

To evaluate the effects of H.E.L.P. apheresis on lipid profile, Lp(a) level, and some inflammatory adypocytokines in patients with high cardiovascular risk.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Dyslipidemia

Interventions

H.E.L.P. apheresisPROCEDURE

High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * high Lp(a) not responsive to diet and pharmacological treatment Exclusion Criteria: * heart failure * hepatic failure * renal failure

Locations (1)

IRCCS Policlinico S. Matteo

Pavia, Italy

Outcomes

Primary Outcomes

Lp(a) reduction

We will evaluate the efficacy of apheretic technique through the reduction of Lp(a) in the plasma sample expressed by mg/dL.

Time frame: 1 year

Secondary Outcomes

Inflammatory adypocytokines

We will evaluate the efficacy of apheretic technique through the improvement of inflammatory adypocytokines in the plasma sample.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.